PhaSER Biomedical获盖茨基金会270万美元资助，推进8HUM模型与HERALD AI
PhaSER Biomedical Secures $2.7M Gates Foundation Grant to Scale 8HUM Preclinical Models and HERALD AI
药企做临床前毒性筛选的老办法是拿小鼠凑合，人代谢和小鼠代谢差太多，漏掉的毒性到人体试验才暴露。这家苏格兰公司用带人类代谢酶基因的转基因小鼠加HERALD AI来补这个坑，盖茨基金会给了270万美元。做药物研发或关注AI制药的人可以看看。
PhaSER Biomedical获得盖茨基金会270万美元资助，用于扩展其8HUM平台和HERALD AI工具。该公司成立于2022年10月，目标是将Dundee大学Roland Wolf教授团队开发的转基因技术商业化，合作方包括CXR Biosciences、Taconic Farms和Scottish Enterprise。
8HUM平台的核心是用人类代谢数据替代传统小鼠模型的盲区：通过转基因小鼠携带人类代谢酶基因，让临床前候选药物的毒性验证更贴近真实人体反应，减少动物实验与人体试验之间的结果偏差。HERALD AI则在此基础上处理和预测候选药物数据。
这笔资助指向全球健康药物研发场景，如抗结核、抗疟等药物的临床前验证需求。对药企和CRO而言，人源化代谢模型加AI预测的组合正在成为传统毒理学流程的补充选项。
PhaSER Biomedical Secures $2.7M Gates Foundation Grant to Scale 8HUM Preclinical Models and HERALD AI
What You Should Know The 8HUM Platform: Replacing Murine Blind Spots with Human Metabolic Ground Truth Founded in October 2022 to commercialize transgenic technology developed through a collaboration between Professor Roland Wolf at the University of Dundee, CXR Biosciences, Taconic Farms, and Scottish Enterprise, PhaSER Biomedical re-engineers preclinical candidate validation: Professor Roland Wolf, Founder of ... Read More
This report is categorized under AITOP's "Products" desk, focusing on Europe's AI governance and technology ecosystem. Within our cross-regional analytical framework, it directly maps to AI developer toolchains, coding agents, and engineering workflows. Key entities and technical topics under continuous tracking include PhaSER Biomedical, HERALD AI, 8HUM, 药物研发.
Source attribution: curated from HIT Consultant (@Jasmine Pennic).
